Bredt David's Form 4 filing
Rapport Therapeutics, Inc. (RAPP) · filed Jan 5, 2026
- Accession no.
- 0001193125-26-002470
- Filed
- Jan 5, 2026
- Trade date
- Dec 31, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $197.3K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bredt DavidCIK 0002022087 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.04 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.